Fuller & Thaler Asset Management Inc. Has $1.09 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• Fuller & Thaler Asset Management Inc. increased its stake in IQVIA Holdings by 29.8%, holding 6,179 shares valued at approximately $1,089,000 at the end of the first quarter.
• Analysts maintain a positive outlook for IQVIA, with an average target price of $228.62 and 17 analysts rating the stock as a Buy.
• In the first quarter, several hedge funds also made significant modifications to their IQVIA holdings, reflecting a broad institutional interest in the company.

Fuller & Thaler Asset Management Inc. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 29.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 6,179 shares of the medical research company's stock after purchasing an additional 1,420 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in IQVIA were worth $1,089,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Pacer Advisors Inc. increased its stake in IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after acquiring an additional 854,732 shares during the period. JPMorgan Chase & Co. increased its stake in IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after acquiring an additional 798,534 shares during the period. D. E. Shaw & Co. Inc. increased its stake in IQVIA by 211.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after acquiring an additional 655,153 shares during the period. Nuveen LLC bought a new stake in IQVIA in the first quarter valued at about $76,328,000. Finally, Cadian Capital Management LP bought a new stake in IQVIA in the fourth quarter valued at about $78,604,000. Institutional investors own 89.62% of the company's stock.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on IQV. Barclays upped their target price on shares of IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and lowered their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Truist Financial upped their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Price Performance

IQVIA stock traded up $5.5970 during trading hours on Friday, hitting $190.9870. 1,619,418 shares of the stock were exchanged, compared to its average volume of 1,441,272. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The business's 50-day moving average is $173.70 and its two-hundred day moving average is $168.26. The stock has a market capitalization of $32.47 billion, a P/E ratio of 27.64, a P/E/G ratio of 2.10 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the business earned $2.64 earnings per share. IQVIA's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.